Source comparison
CJC-1295 No DAC vs GHRP-2 Acetate: Research Comparison
Primary Mechanism GHRH receptor agonist. Amplifies endogenous GH pulses via pituitary cAMP signaling Ghrelin receptor agonist. Triggers GH release + reduces somatostatin inhibition GHRP-2 produces sharper acute spikes; CJC provides sustained pulse amplificatio
This comparison does not assign a generated winner or score.
- Primary Mechanism
- GHRH receptor agonist. Amplifies endogenous GH pulses via pituitary cAMP signaling
- Ghrelin receptor agonist. Triggers GH release + reduces somatostatin inhibition
- GHRP-2 produces sharper acute spikes; CJC provides sustained pulse amplification. Neither downregulates receptors when dosed correctly.
- Half-Life
- ~30 minutes (subcutaneous)
- ~20–30 minutes (subcutaneous)
- Both clear rapidly, preserving natural pulsatility. Dosing frequency (2–3×/day) reflects this short duration.
- Standard Dose
- 100mcg per injection, 1–3×/day
- 100–300mcg per injection, 1–3×/day (100–150mcg most common)
- Stacking at 100mcg each produces 3–5× synergistic GH response vs either peptide alone.
- Peak GH Response (Monotherapy)
- 5–15 ng/mL within 30–60 min
- 10–25 ng/mL within 20–30 min
- GHRP-2 spikes higher alone, but combined protocol elevates GH to 30–50 ng/mL.
- Receptor Desensitization Risk
- Minimal. No DAC version doesn't suppress GHRH axis
- Low at standard doses; high doses (>300mcg) may blunt ghrelin receptor sensitivity over time
- Correct dosing + cycling prevents desensitization. Chronic supraphysiological dosing of either peptide risks negative feedback.
- Primary Research Applications
- Amplifying natural GH pulses without chronic elevation; longevity and metabolic health studies
- Acute GH secretion studies; appetite regulation research; body composition protocols
- CJC is preferred for circadian-aligned protocols; GHRP-2 for dose-response GH studies.
- The comparison table above reflects pharmacokinetic data from peer-reviewed endocrinology research. When evaluating CJC-1295 no DAC vs GHRP-2 Acetate which better comparison outcomes, the correct framing isn't superiority. It's application specificity. Modified GRF is the tool for amplifying endogenous pulses without disrupting feedback loops. GHRP-2 is the tool for triggering immediate, high-amplitude secretion when natural pulsatility is suboptimal. Most researchers use both.